Your browser doesn't support javascript.
loading
Inherited TP53 Variants and Risk of Prostate Cancer.
Maxwell, Kara N; Cheng, Heather H; Powers, Jacquelyn; Gulati, Roman; Ledet, Elisa M; Morrison, Casey; Le, Anh; Hausler, Ryan; Stopfer, Jill; Hyman, Sophie; Kohlmann, Wendy; Naumer, Anne; Vagher, Jennie; Greenberg, Samantha E; Naylor, Lorraine; Laurino, Mercy; Konnick, Eric Q; Shirts, Brian H; AlDubayan, Saud H; Van Allen, Eliezer M; Nguyen, Bastien; Vijai, Joseph; Abida, Wassim; Carlo, Maria I; Dubard-Gault, Marianne; Lee, Daniel J; Maese, Luke D; Mandelker, Diana; Montgomery, Bruce; Morris, Michael J; Nicolosi, Piper; Nussbaum, Robert L; Schwartz, Lauren E; Stadler, Zsofia; Garber, Judy E; Offit, Kenneth; Schiffman, Joshua D; Nelson, Peter S; Sartor, Oliver; Walsh, Michael F; Pritchard, Colin C.
Afiliación
  • Maxwell KN; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J. Crescenz Veterans Affairs M
  • Cheng HH; Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Powers J; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Gulati R; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Ledet EM; Tulane Cancer Center, Tulane Medical School, New Orleans, LA, USA.
  • Morrison C; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Le A; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Hausler R; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84148.
  • Stopfer J; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hyman S; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kohlmann W; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Naumer A; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Vagher J; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Greenberg SE; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Naylor L; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Laurino M; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Konnick EQ; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Shirts BH; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Brotman Baty Institute for Precision Medicine, Seattle, WA, USA.
  • AlDubayan SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Nguyen B; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vijai J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Abida W; Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carlo MI; Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Dubard-Gault M; Seattle Cancer Care Alliance, Seattle, WA, USA; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Lee DJ; Department of Surgery, Division of Urology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia PA, 19104.
  • Maese LD; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Mandelker D; Diagnostic Molecular Genetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Montgomery B; Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA 98108.
  • Morris MJ; Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nicolosi P; Invitae Corporation, San Francisco, CA, USA.
  • Nussbaum RL; Invitae Corporation, San Francisco, CA, USA.
  • Schwartz LE; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Stadler Z; Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Garber JE; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Offit K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schiffman JD; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA; PEEL Therapeutics, Inc., Salt Lake City, UT, USA.
  • Nelson PS; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Sartor O; Tulane Cancer Center, Tulane Medical School, New Orleans, LA, USA.
  • Walsh MF; Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Brotman Baty Institute for Precision Medicine, Seattle, WA, USA. Electronic address: cpritch@uw.edu.
Eur Urol ; 81(3): 243-250, 2022 Mar.
Article en En | MEDLINE | ID: mdl-34863587
ABSTRACT

BACKGROUND:

Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome (LFS). However, there is no known association of prostate cancer with gTP53.

OBJECTIVE:

To determine whether gTP53 predisposes to prostate cancer. DESIGN, SETTING, AND

PARTICIPANTS:

This multi-institutional retrospective study characterizes prostate cancer incidence in a cohort of LFS males and gTP53 prevalence in a prostate cancer cohort. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

We evaluated the spectrum of gTP53 variants and clinical features associated with prostate cancer. RESULTS AND

LIMITATIONS:

We identified 31 prostate cancer cases among 163 adult LFS males, including 26 of 54 aged ≥50 yr. Among 117 LFS males without prostate cancer at the time of genetic testing, six were diagnosed with prostate cancer over a median (interquartile range [IQR]) of 3.0 (1.3-7.2) yr of follow-up, a 25-fold increased risk (95% confidence interval [CI] 9.2-55; p < 0.0001). We identified gTP53 in 38 of 6850 males (0.6%) in the prostate cancer cohort, a relative risk 9.1-fold higher than that of population controls (95% CI 6.2-14; p < 0.0001; gnomAD). We observed hotspots at the sites of attenuated variants not associated with classic LFS. Two-thirds of available gTP53 prostate tumors had somatic inactivation of the second TP53 allele. Among gTP53 prostate cancer cases in this study, the median age at diagnosis was 56 (IQR 51-62) yr, 44% had Gleason ≥8 tumors, and 29% had advanced disease at diagnosis.

CONCLUSIONS:

Complementary analyses of prostate cancer incidence in LFS males and gTP53 prevalence in prostate cancer cohorts suggest that gTP53 predisposes to aggressive prostate cancer. Prostate cancer should be considered as part of LFS screening protocols and TP53 considered in germline prostate cancer susceptibility testing. PATIENT

SUMMARY:

Inherited pathogenic variants in the TP53 gene are likely to predispose men to aggressive prostate cancer.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Síndrome de Li-Fraumeni Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Humans / Male / Middle aged Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Síndrome de Li-Fraumeni Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Humans / Male / Middle aged Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article